New combo therapy hopes to beat tough blood cancers
NCT ID NCT07294677
First seen Jan 07, 2026 · Last updated May 16, 2026 · Updated 21 times
Summary
This study tests adding a new drug called capivasertib to a standard treatment for adults with certain types of leukemia or lymphoma that have come back or not responded to treatment. The standard treatment includes venetoclax and low-intensity chemotherapy. The study has three parts: first, finding a safe dose of capivasertib; second, checking safety in more people; and third, comparing the new combination to the standard treatment alone. About 104 participants will take part.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for LEUKEMIA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
University of Chicago Medicine Comprehensive Cancer Center
RECRUITINGChicago, Illinois, 60637, United States
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.